18-Fluoro-deoxyglucose uptake in inflammatory hepatic adenoma: A case report. by Liu, Willy et al.
Willy Liu, Jean Delwaide, Noella Bletard, Philippe Delvenne, Paul Meunier, Roland Hustinx, Olivier Detry
CASE REPORT
562 April 18, 2017|Volume 9|Issue 11|WJH|www.wjgnet.com
18-Fluoro-deoxyglucose uptake in inflammatory hepatic 
adenoma: A case report
Willy Liu, Olivier Detry, Department of Abdominal Surgery and 
Transplantation, CHU Liege (CHU-ULg), B4000 Liege, Belgium
Jean Delwaide, Department of Hepato-gastroenterology, CHU 
Liege (CHU-ULg), B4000 Liege, Belgium
Noella Bletard, Philippe Delvenne, Department of Pathology, 
CHU Liege (CHU-ULg), B4000 Liege, Belgium
Paul Meunier, Department of Radiology, CHU Liege (CHU-
ULg), B4000 Liege, Belgium
Roland Hustinx, Department of Nuclear Imaging, CHU Liege 
(CHU-ULg), B4000 Liege, Belgium
Author contributions: Liu W collected the data, performed 
the literature review and wrote the paper; Delwaide J took care 
of the patient and collected the data; Bletard N and Delvenne 
P performed the pathology analyses and figures; Meunier P 
performed the radiologic investigations; Hustinx R performed 
the PET-CTs and wrote the manuscript; Detry O followed and 
operated the patients on and wrote the manuscript. 
Institutional review board statement: According to the Belgian 
Law and medical ethics, there is no need for an institutional review 
board for a retrospective report of an anonymized patient’s case. 
Informed consent statement: According to the Belgian Law 
and medical ethics, there is no need for a consent form for the 
retrospective report of an anonymized patient’s case. 
Conflict-of-interest statement: The authors have no conflict-
of-interest to disclose concerning this manuscript. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Olivier Detry, Professor, Department 
of Abdominal Surgery and Transplantation, CHU Liege (CHU-




Received: August 28, 2016
Peer-review started: August 29, 2016
First decision: November 21, 2016 
Revised: January 25, 2017
Accepted: March 21, 2017
Article in press: March 21, 2017
Published online: April 18, 2017 
Abstract
Positron emission tomography computed tomography 
(PET-CT) using 18-Fluoro-deoxyglucose (18FDG) is an 
imaging modality that reflects cellular glucose meta-
bolism. Most cancers show an uptake of 18FDG and 
benign tumors do not usually behave in such a way. 
The authors report herein the case of a 38-year-old 
female patient with a past medical history of cervical 
intraepithelial neoplasia and pheochromocytoma, in 
whom a liver lesion had been detected with PET-CT. The 
tumor was laparoscopically resected and the diagnosis 
of inflammatory hepatic adenoma was confirmed. This is 
the first description of an inflammatory hepatic adenoma 
with an 18FDG up-take.
Key words: Liver surgery; Liver tumor; Liver cancer; 
Benign tumor; Laparoscopy; Prognosis
© The Author(s) 2017. Published by Baishideng Publishing 
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Core tip: In cancer therapy, the use of 18-Fluoro-
deoxyglucose (18FDG) positron emission tomography 
computed tomography as a staging or prognostic tool, is 
increasing. This is also the case for primary or secondary 
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liver cancer. In this paper, the authors report the first 
description of an inflammatory hepatic adenoma with 
18FDG uptake. 
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adenoma: A case report. World J Hepatol 2017; 9(11): 562-566 
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INTRODUCTION
Hepatocellular adenomas (HCAs) are rare benign hepatic 
tumors that are more frequent in women and have 
been associated with oral contraceptive use[1]. The risk 
of malignant transformation of HCAs is small but non-
negligible[2]. The commonest complication of HCAs is 
bleeding, an occurrence which has been linked to multiple 
factors such as the size of the adenoma, pregnancy, 
visualization of lesional arteries, left lateral lobe location and 
exophytic growth. Due to these risks, recent guidelines have 
recommended the resection of adenomas that present: 
A diameter larger than 50 mm, signs of hepatocarcinoma 
or focal dysplasia, activated β-catenin mutation, high 
level of serum alfafoetoprotein, hepatocellular adenomas 
developing in male gender or hepatocellular adenomas 
developing in a glycogen storage disease[3]. The resection 
is regularly performed as laparoscopic hepatectomy[4]. 
Positron emission tomography computed tomography 
(PET-CT) using 18-Fluoro-deoxyglucose (18FDG) is an 
imaging modality that is based on an enhancement of 
glucose consumption, a distinguishing feature of most 
cancers that is in part related to the over-expression of 
GLUT-1 glucose transporters and increased hexokinase 
activity. The use of PET-CT in primary or secondary liver 
cancer is increasing[5,6]. As HCAs are benign lesions, 
they are not assumed to be 18FDG-avid, except in some 
rare cases. To the best of their knowledge, the authors 
described herein the first report of 
18FDG uptake by an 
inflammatory HCA (I-HCA), and reviewed the literature 
for other reports of 18FDG uptake in other types of liver 
adenoma. 
CASE REPORT
A 38-year-old female patient had a past medical history 
of cervical intraepithelial neoplasia treated with cervical 
conisation, and a pheochromocytoma that was laparo-
scopically resected in 2011. She was followed up with 
yearly magnetic resonance imaging (MRI) that demon-
strated a segment 1 liver tumor whose size increased of 
20 mm in two years. This 50-mm lesion bore the MRI 
features of HCA, showing a heterogeneous signal inten-
sity on T-2 weighted images and low-signal intensity on 
T-1 weighted images. The lesion was slowly and gradually 
enhanced after injection of gadolinium without significant 
wash-out on portal phase (Figure 1). In addition, a left 
renal cyst was noticed, described as type 3 according to 
the Bosniak classification. An 
18FDG PET-CT (Figure 2) was 
performed to further confirm the nature of the hepatic 
lesion and exclude extrahepatic metastases. The liver 
lesion appeared hypermetabolic with a standardized 
uptake value (SUVmax) of 9.3. A percutaneous biopsy 
was performed and immunohistology allowed the 
diagnosis of I-HCA. Blood carcinoembryonic antigen, 
carbohydrate antigen 19.9 and alphafoetoprotein were 
negative. A discussion in a multi-disciplinary oncological 
team meeting led to the decision of the resection of 
the hepatic lesion. A laparoscopic resection of hepatic 
segment 1 was performed, extended to segments 2 
and 3 due to the location of the tumor at the junction 
between the inferior vena cava, the left and middle 
hepatic veins and the left branch of the portal vein. 
During the same anesthesia, the left kidney mass was 
resected through a lombotomy, following the preferences 
of the urologist. The surgical specimen was analyzed 
and showed slightly clarified hepatocytes scattered 
throughout the lesion, fibrous tracts with vascular struc-
tures within, probably arteries with thick walls (Figure 3). 
Some inflammatory components surrounded these arteries 
and there was no significant sinusoidal dilatation. At 
immunohistochemistry, serum amyloid A was negative 
and anti-C reactive protein antibodies showed a signi-
ficant expression of the inflammatory protein around 
blood vessels, confirming I-HCA (Figure 4). Inflammatory 
cells were CD3 positive (Figure 5). The immediate post-
operative state was excellent, without significant pain and 
fast oral feeding. The length of hospital stay was 5 d. The 
patient was seen again one month later for an evaluation 
visit and no particular problems were observed. 
DISCUSSION
This report describes the occurrence of a 50-mm I-HCA 
that was highly avid for 18FDG at PET-CT. The exact 
nature of this I-HCA was confirmed by surgical resection. 
To the best of the authors’ knowledge, this is the first 
report of 18FDG uptake by an I-HCA. HCAs are classified 
into four types, according to their genetic and histologic 
features (Table 1): HNF1α inactivated HCA (H-HCA), 
β-catenin mutated HCA (β-HCA), I-HCA and unclassified 
HCA[7,8]. The actual risk of malignancy of all HCAs is 
evaluated at 4.2%[2,3]. The β-HCA subtype is associated 
with the highest risk of malignant transformation and 
must be resected (Table 1). After literature review, the 
authors found 22 other HCA cases with 18FDG uptake 
in PET-CT[9-19] (Table 2), and none of them was the 
inflammatory type. Eighteen of them have a description 
of the histological findings with steatosis. Twelve reported 
a final diagnosis, which was either HNF1α or hepatic 
adenomatosis. 
The uptake of 18FDG results from the increased meta-
bolism of the cell. The intracellular FDG accumulation 
is proportional to the amount of glucose utilization[20] 
and most cancers do have increased cellular activity. 
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The differential diagnosis of benign 18FDG avid hepatic 
lesions might include focal steatosis, infectious, parasitic 
or inflammatory processes (e.g., hepatic abscess, cryp-
tococcal infection, hepatic tuberculoma) and hepatic 
adenoma[21,22]. Focal fatty infiltration has been reported to 
be PET-avid[23]. In fact, as a response to fat accumulation, 
a subacute inflammatory hepatic reaction with infiltration 
of activated Kupffer cells may occur, resulting in a higher 
SUVmax than adjacent normal liver parenchyma. As 
said above, five cases of hepatic adenoma showed fatty 
changes but none of them were of the inflammatory type. 
Only one had a few inflammatory infiltrates. Maybe the 
fatty change itself was sufficient enough to induce a PET-
avid response, without obvious inflammatory infiltrate in 
histological examination. It is also possible, as suggested 
by Nakashima et al[14], that the high expression of glucose 
transporters might be responsible for the increased up-
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Figure 1  T1 weighted magnetic resonance imaging with gadolinium injection, showing a 50-mm tumor in segment 1 (arrow). A: Arterial phase; B: Portal 
venous phase.
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Figure 2  Positron emission tomography computed tomography using 18-fluoro-deoxyglucose showing the 18-fluoro-deoxyglucose avidity of the segment 




Figure 3  Pathology of the tumor that contains thickened arteries 
(arrows), inflammatory infiltrate (arrowheads), sinusoidal dilatation (a) 
(hematoxylin-eosin stain).
100 μm
Figure 4  Immunohistochemistry with anti-C reactive protein antibodies, 
positive in the adenomatous hepatocytes (arrow), confirming inflam-
matory hepatocellular adenoma.
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LFABP gene ablation significantly increased the in-vitro 
expression of GLUT-2 but not that of GLUT-1[24]. Another 
study demonstrated that HNF1α-inactivated HCAs activate 
glycolysis due to a strong up-regulation of glucokinase[25]. 
These two components are features of most cancers (rise 
of GLUT-1 and hexokinase activity) with features of H-HCA 
(rise of GLUT-2 and glucokinase). However, due to the few 
reports published in literature, no conclusion can be made 
on the risk of cancer development in HCA with uptake of 
18
FDG. Prospective and large series are needed to confirm 
the role of PET-CT in HCA evaluation and prognosis. 
COMMENTS
Case characteristics 
A 5-cm liver tumor was diagnosed in a 38-year-old woman. 
Clinical diagnosis 
This tumor was asymptomatic and described at follow-up imaging after surgical 
resection of a pheochromocytoma. 
Differential diagnosis 
Adenoma, hepatocellular carcinoma, other primary or metastatic hepatic 
tumors.
Laboratory diagnosis 
Blood tumor markers, and particularly alphafoetoprotein, were negative. 
Imaging diagnosis 
Magnetic resonance imaging was compatible with hepatocellular adenoma, 
but the lesion was 18-Fluoro-deoxyglucose (
18
FDG) avid at positron emission 
tomography computed tomography (PET-CT).  
Pathological diagnosis 
Percutaneous biopsy and surgical specimen conformed inflammatory hepato-
cellular adenoma (I-HCA).
Treatment 
Laparoscopic liver R0 resection.
Related reports 
To the authors’ knowledge, this case is the first report of a PET-CT FDG-avid 
I-HCA. 
Term explanation 
Hepatocellular adenomas are benign liver lesions whose imaging diagnosis 
could be uncertain. 
Experiences and lessons 
PET-CT positivity is not necessary linked to cancerous degeneration in liver 
adenomas. 
HCA subtype Abbreviation Proportion Markers Malignant transformation
HNF1α inactivated H-HCA 35%-40% LFABP Rare
β-catenin activated β-HCA 10% β-catenin+/GS+ activated Yes
Inflammatory I-HCA 50% CRP+ No
Unclassified U-HCA   5% None No
Table 1  Classification of hepatocellular adenomas
HCA: Hepatocellular adenoma.
Ref. Gender Age (yr) Size (mm) SUVmax Diagnosis
[7] Female 41 10 NA HCA
[8] Female 37 33 5 H-HCA
[9] NA 44 30    6.2 HCA
[10] Female 52 NA 4.09-9.8 Hepatic adenomatosis
[11] Female 65 30 NA Necrotic HCA
[12] Male 69 40 10.4 H-HCA
[13] 4 cases NA 73 ± 15   6 ± 0.5 HCA
[14] Female 34 20-30   3.9 HCA
[15] Male 73 25  11.9 Fatty liver
[16] Female 44 23   7.9 H-HCA
[17] 9 cases 49 ± 16 27 ± 15 8.2 ± 4.3 H-HCA
This case Female 38 50   9.3 I-HCA
Table 2  Cases of 18-fluoro-deoxyglucose-avid hepatocellular adenomas reported in literature
HCA: Hepatocellular adenoma; 18FDG: 18-fluoro-deoxyglucose; H-HCA: HNF1α inactivated HCA; I-HCA: Inflammatory HCA; NA: Not available.
100 μm
Figure 5  Immunohistochemistry with anti-CD3 antibodies, positive in the 
inflammatory cells (arrow).
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Peer-review 
This paper reported a case of PET-avid hepatocellular adenomas and reviews 
related literature to show variety cause of PET-avid HCA. 
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